镓- DOTATATE 正电子发射断层扫描/计算机断层扫描在神经内分泌肿瘤的诊断、治疗、随访和预后中的应用。
The utility of Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.
机构信息
Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sackler Faculty of Medicine, Tel Aviv University, Israel.
出版信息
Future Oncol. 2018 Jan;14(2):111-122. doi: 10.2217/fon-2017-0393. Epub 2017 Oct 26.
Abstract
Neuroendocrine tumors (NETs) are rare neoplasms that emerge mainly from the GI tract, pancreas and respiratory tract. The incidence of NETs has increased more than sixfold in the last decades. NETs typically express somatostatin receptors on their cell surface, which can be targeted by 'cold' somatostatin analogs for therapy or by 'hot' radiolabeled somatostatin analogs for tumor localization and treatment. 68-Gallium-DOTA peptides (DOTATATE, DOTATOC, DOTANOC) positron emission tomography/computed tomography is a highly accurate imaging modality for NETs that has been found to be more sensitive for NET detection than other imaging modalities. In the current review, we will discuss the clinical utility of 68-Gallium-DOTATATE positron emission tomography/computed tomography for the diagnosis and management of patients with NETs.
摘要
神经内分泌肿瘤（NETs）是一种罕见的肿瘤，主要来源于胃肠道、胰腺和呼吸道。在过去几十年中，NETs 的发病率增加了六倍以上。NETs 通常在其细胞表面表达生长抑素受体，这些受体可被“冷”生长抑素类似物靶向用于治疗，或被“热”放射性标记生长抑素类似物靶向用于肿瘤定位和治疗。68-镓-DOTA 肽（DOTATATE、DOTATOC、DOTANOC）正电子发射断层扫描/计算机断层扫描是一种高度准确的 NETs 成像方式，其对 NETs 的检测灵敏度高于其他成像方式。在本综述中，我们将讨论 68-镓-DOTATATE 正电子发射断层扫描/计算机断层扫描在 NETs 患者的诊断和管理中的临床应用。
相似文献
1
The utility of Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.
Future Oncol. 2018 Jan;14(2):111-122. doi: 10.2217/fon-2017-0393. Epub 2017 Oct 26.
2
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.
3
Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.
Acta Radiol. 2014 May;55(4):389-98. doi: 10.1177/0284185113496679. Epub 2013 Aug 8.
4
Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
J Surg Oncol. 2020 Mar;121(3):480-485. doi: 10.1002/jso.25812. Epub 2019 Dec 18.
5
F-AlF-NOTA-Octreotide Outperforms Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.
J Nucl Med. 2023 Apr;64(4):632-638. doi: 10.2967/jnumed.122.264563. Epub 2022 Oct 20.
6
Neuroendocrine Tumor Diagnosis and Management: Ga-DOTATATE PET/CT.
AJR Am J Roentgenol. 2018 Aug;211(2):267-277. doi: 10.2214/AJR.18.19881. Epub 2018 Jul 5.
7
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
J Vis Exp. 2019 Apr 17(146). doi: 10.3791/59358.
8
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.
9
Prognostic Utility of Total Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors.
Gastroenterology. 2018 Mar;154(4):998-1008.e1. doi: 10.1053/j.gastro.2017.11.008. Epub 2017 Nov 16.
10
Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using Ga-DOTATOC and Ga-DOTATATE.
J Nucl Med. 2020 Feb;61(2):217-221. doi: 10.2967/jnumed.119.228072. Epub 2019 Jul 13.
引用本文的文献
1
Diagnosis and treatment of renal neuroendocrine tumors: a case report and literature review.
Front Oncol. 2025 Jun 18;15:1544525. doi: 10.3389/fonc.2025.1544525. eCollection 2025.
2
[Ga]‑DOTA‑conjugated somatostatin receptor‑targeting peptide PET for the differentiation between meningioma and glioblastoma: A case report and review of the literature.
Oncol Lett. 2025 Feb 24;29(4):199. doi: 10.3892/ol.2025.14945. eCollection 2025 Apr.
3
Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.
Chem Biomed Imaging. 2023 Nov 15;2(3):168-184. doi: 10.1021/cbmi.3c00093. eCollection 2024 Mar 25.
4
Two synchronous primary mesenteric neuroendocrine tumors in a patient: a case report.
Front Surg. 2024 Apr 4;11:1323468. doi: 10.3389/fsurg.2024.1323468. eCollection 2024.
5
Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.
Pharmaceuticals (Basel). 2024 Mar 14;17(3):373. doi: 10.3390/ph17030373.
6
Comparison of Ga-DOTATATE Positron Emmited Tomography/Computed Tomography and Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Detection of Liver Metastases from Well-Differentiated Neuroendocrine Tumors.
Curr Oncol. 2024 Jan 16;31(1):521-534. doi: 10.3390/curroncol31010036.
7
Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines.
Cancers (Basel). 2022 Dec 31;15(1):295. doi: 10.3390/cancers15010295.
8
Highly variable biodistribution of Ga labeled somatostatin analogues Ga-DOTA-NOC and Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.
Hepatobiliary Surg Nutr. 2022 Oct;11(5):654-661. doi: 10.21037/hbsn-21-554.
9
An unusual case of chronic diarrhea: a case report.
Intern Emerg Med. 2022 Nov;17(8):2343-2347. doi: 10.1007/s11739-022-03055-0. Epub 2022 Jul 30.
10
Value of [Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.
EJNMMI Res. 2022 May 7;12(1):28. doi: 10.1186/s13550-022-00900-3.
本文引用的文献
1
Long-Acting Somatostatin Analog Therapy Differentially Alters Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.
J Nucl Med. 2018 Feb;59(2):223-227. doi: 10.2967/jnumed.117.192203. Epub 2017 Jul 20.
2
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
3
Evaluation of Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with Ga-DOTATOC PET/CT.
Eur Radiol. 2017 Oct;27(10):4091-4099. doi: 10.1007/s00330-017-4803-2. Epub 2017 Apr 24.
4
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
Theranostics. 2017 Mar 1;7(5):1149-1158. doi: 10.7150/thno.18068. eCollection 2017.
5
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.
Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13.
6
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.
Neuroendocrinology. 2017;105(3):212-244. doi: 10.1159/000471879. Epub 2017 Mar 30.
7
Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total Ga-DOTATATE-Avid tumor volume measurements.
Eur J Endocrinol. 2017 May;176(5):575-582. doi: 10.1530/EJE-16-1079.
8
Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis.
J Nucl Med. 2017 Sep;58(9):1452-1458. doi: 10.2967/jnumed.117.191197. Epub 2017 Mar 9.
9
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.
Neuroendocrinology. 2017;105(3):196-200. doi: 10.1159/000457956. Epub 2017 Feb 11.
10
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
Zotero 插件